A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Joseph Mıkhael, Karim Belhadj‐Merzoug, Cyrille Hulin, Laure Vincent, Philippe Moreau, Cristina Gasparetto, Luděk Pour, Ivan Špıčka, Ravi Vij, Jeffrey A. Zonder, Djordje Atanackovic, Nashat Gabrail, Thomas G. Martin, Aurore Perrot, Samira Bensfia, Qilong Weng, Claire Brillac, Dorothée Sémiond, Sandrine Macé, Kathryn P. Corzo, Xavier Leleu